Pfizer Inc. today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in ...
Up to a third of people worldwide have shoulder pain; it’s one of the most common musculoskeletal complaints. But medical ...
When a new type of high-resolution computed tomography (CT) device was unveiled in Japan in 2017, it revolutionized the field, offering more than twice the resolution of conventional CT devices. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results